Palvella Therapeutics, Inc. Common Stock

Day range

$123.83 – $127.20

Open

$126.52

Prev close

$125.10

Volume

108.35K

Market cap

$1.8B

Shares out

14.41M

P/E

—

P/S

—

P/B

8.31

P/FCF

—

ROE

-28.4%

ROA

-24.3%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Investor presentationAug 4, 2026

  On August 4, 2026, the Company will hold its earnings call and use a slide presentation in conjunction with the earnings call. A copy of the presentation is furnished herewith as Exhibit 99.2.

• Investor presentationJul 14, 2026

  On July 14, 2026, Palvella Therapeutics, Inc. (the "Company") posted a corporate presentation to its website, which representatives of the Company will use in various meetings with investors from time to time.

• Equity compensation grantJun 30, 2026

  on the Appointment Date, pursuant to the Director Compensation Policy, Mr. Pauls was granted an option to purchase 6,000 shares of the Company's common stock, par value $0.001 per share, which vests in equal monthly installments over thirty-six months, subject to continued service.

• Clinical trial resultsMay 20, 2026

  new positive clinical data and findings from the Company's Phase 3 SELVA and Phase 2 TOIVA studies were reported at the International Society for the Study of Vascular Anomalies World Congress 2026

• Listing transferMay 13, 2026

  Palvella Therapeutics, Inc. received approval from the Nasdaq Listing Qualifications Department to move the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Market, effective with the open of business on May 13, 2026.

Days to cover

10.7

Short interest

2.52M

Avg volume

236.26K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally
  positiveThe Motley Fool· Jun 27, 2026
• Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal
  positiveThe Motley Fool· Mar 25, 2026
• Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
  positiveBenzinga· Mar 2, 2026
• Palvella Therapeutics Announces Pricing of Upsized Public Offering
  positiveGlobeNewswire Inc.· Feb 25, 2026
• Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
  positiveGlobeNewswire Inc.· Feb 23, 2026